Domain Associates

WindMIL Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Princeton, New Jersey. It focuses on developing innovative cell therapies for cancer patients by translating insights from bone marrow immunology. The company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs), which are derived from memory T cells found in the bone marrow. By reactivating dormant T-cells and utilizing bone marrow-derived lymphocytes, WindMIL Therapeutics aims to create effective immunotherapies that harness the unique properties of the bone marrow, ultimately improving treatment options for oncology patients.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

NPS Pharmaceuticals is a biopharmaceutical company based in Bedminster, New Jersey, dedicated to developing therapeutic products for gastrointestinal and endocrine disorders, particularly focusing on rare diseases. The company offers Gattex and Revestive for the treatment of short bowel syndrome (SBS) in adults, as well as a pediatric formulation of Gattex/Revestive that is undergoing clinical trials. Additionally, NPS Pharmaceuticals is developing Natpara, a bioengineered parathyroid hormone replacement therapy for hypoparathyroidism, which currently lacks approved treatment options. The company is also advancing NPSP795, a calcilytic agent in clinical development for autosomal dominant hypocalcemia, an ultra-rare genetic disorder. NPS Pharmaceuticals collaborates with several major pharmaceutical companies and has numerous royalty-based products in its portfolio, addressing conditions such as hyperparathyroidism and pain management. With a commitment to innovation and patient-centric solutions, NPS Pharmaceuticals aims to transform the lives of patients facing significant unmet medical needs in the rare disease space.